Skip to main content
Premium Trial:

Request an Annual Quote

Plexera, JPT Sign Distribution, Proteomics Application Development Agreement

NEW YORK (GenomeWeb) – Plexera Biotechnology and JPT Peptide Technologies today announced a deal to distribute JPT's peptide-based products and services in China and to develop peptide-based applications on Plexera's PlexArray HT platform for high-throughput proteomics screening. 

Plexera will distribute JPT's products and services to the Chinese proteomics, immunotherapy, and vaccine markets, the companies said. Financial and other terms of the agreement were not disclosed. 

"This partnership represents a strategic cornerstone in our continued efforts to address all major global markets with our broad portfolio of proprietary and high-quality products for the discovery of novel biomarkers and the development of immunotherapies and vaccines," JPT CEO Holger Wenschuh said in a statement. 

JPT is a subsidiary of BioNTech and is based in Berlin. Its key technologies include PepStar for high-content peptide microarrays and SpikeTide for protein biomarker quantification. 

Plexera, headquartered in Woodinville, Wash., provides surface plasmon resonance imaging-based solutions for chemical and biological applications. 

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.